Multiple Myelomas News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Multiple Myeloma: Second Relapse and Beyond - OncLive



OncLive
 
Multiple Myeloma: Second Relapse and Beyond 
OncLive
Rafael Fonseca, MD: In myelomas, our patients go through treatment. We want to maximize the duration of first-line therapy. In fact, if you look at optimal induction followed by stem cell transplant and then maintenance, you can start envisioning about ...

and more » 


Discovery: Aiding a Fragile Mussel, Trial Seeks Multiple Myeloma Patients, 3-D Universe - dallasinnovates.com



dallasinnovates.com
 
Discovery: Aiding a Fragile Mussel, Trial Seeks Multiple Myeloma Patients, 3-D Universe 
dallasinnovates.com
Anderson is associate professor of internal medicine with UT Southwestern's Simmons Cancer Center. ?We are very excited to be pioneering this promising treatment for multiple myeloma in this region,? Anderson said. ?These are patients who either did ...

 


Case Study 1: A Diagnosis of Stage II Multiple Myeloma - OncLive - OncLive



OncLive
 
Case Study 1: A Diagnosis of Stage II Multiple Myeloma - OncLive 
OncLive
Gareth Morgan, MD, PhD; Rafael Fonseca, MD; and Thomas G. Martin, MD, discuss the diagnosis and upfront treatment of a 56-year-old man with stage International Scoring System-II multiple myeloma, including considerations for maintenance therapy.

and more » 


Pomalidomide Effective in Multiple Myeloma With Renal Impairment - OncLive



OncLive
 
Pomalidomide Effective in Multiple Myeloma With Renal Impairment 
OncLive
Eligible adult patients had a documented diagnosis of multiple myeloma and measurable disease by M-protein or serum free light chain levels. Patients must have received at least 1 antimyeloma regimen, including lenalidomide (Revlimid), and documented ...

 


Denosumab Approaches European Approval for Myeloma - OncLive



OncLive
 
Denosumab Approaches European Approval for Myeloma 
OncLive
?More than 90% of patients with multiple myeloma develop bone lesions over the course of the disease. These can result in fractures and other bone complications,? David M. Reese, MD, senior vice president of Translational Sciences and Oncology at Amgen ...

 


Landgren Discusses Treatment Options for Newly Diagnosed Multiple Myeloma - Targeted Oncology



Targeted Oncology
 
Landgren Discusses Treatment Options for Newly Diagnosed Multiple Myeloma 
Targeted Oncology
Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial ...

 


Multiple Myeloma: Considerations in Treating Relapse - OncLive



OncLive
 
Multiple Myeloma: Considerations in Treating Relapse 
OncLive
Thomas G. Martin, MD: When somebody has relapsed with multiple myeloma, you really have to take a personal approach. There are many factors that you have to consider when you're going to select a regimen for a patient. One of the first things is, is it ...

and more » 


Case Study 1: Follow-Up Strategies for Multiple Myeloma - OncLive



OncLive
 
Case Study 1: Follow-Up Strategies for Multiple Myeloma 
OncLive
Thomas G. Martin, MD: When a patient like this undergoes transplant, typically at 3 months posttransplant we'll do a bone marrow biopsy and an assessment of their myeloma burden. That point in time is when we start them on maintenance-based therapy ...

and more » 


Multiple Myeloma: Understanding and Treating Progression - OncLive



OncLive
 
Multiple Myeloma: Understanding and Treating Progression 
OncLive
If we look at patients who have undergone a single autologous transplant and lenalidomide maintenance, their remission duration is more like 50 months. With primary therapy outside of an autologous transplant, like in the SWOG study, the progression ...

and more » 


Model Identifies Risk of Progression in Smoldering Multiple Myeloma With Greater Precision - Targeted Oncology



Targeted Oncology
 
Model Identifies Risk of Progression in Smoldering Multiple Myeloma With Greater Precision 
Targeted Oncology
Using next-generation sequencing methods, researchers are attempting to combine clinical and genomic biomarkers to identify patients with smoldering multiple myeloma (SMM) who are at high risk for disease progression. The findings demonstrate that ...